Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.34 |
| ▸ | POLB | P06746 | 2/20 | 0.33 |
| ▸ | MEN1 | O00255 | 3/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.33 |
| ▸ | CYP19A1 | P11511 | 2/20 | 0.33 |
| ▸ | FSCN1 | Q16658 | 1/20 | 0.33 |
| ▸ | HTT | P42858 | 2/20 | 0.32 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.32 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.32 |
| ▸ | GRIN2B | Q13224 | 1/20 | 0.32 |
| ▸ | CNR2 | P34972 | 1/20 | 0.32 |
| ▸ | MAPT | P10636 | 1/20 | 0.32 |
| ▸ | THRB | P10828 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4965499 | 0.92 | KDM4E (0.33) | KDM4EALDH1A1POLBMEN1KMT2A | |
| SCHEMBL3495823 | 0.88 | MCHR1 (0.36) | KDM4EALDH1A1POLBMEN1KMT2A | |
| SCHEMBL14302885 | 0.88 | ALDH1A1 (0.37) | KDM4EALDH1A1POLBMEN1KMT2A | |
| SCHEMBL14303283 | 0.88 | KDM4E (0.36) | KDM4EALDH1A1POLBMEN1KMT2A | |
| SCHEMBL4964868 | 0.85 | CYP19A1 (0.39) | KDM4EALDH1A1POLBMEN1KMT2A | |
| SCHEMBL4964875 | 0.84 | KDM4E (0.33) | KDM4EALDH1A1POLBMEN1KMT2A | |
| SCHEMBL14395082 | 0.84 | MDM4 (0.34) | KDM4EALDH1A1POLBMEN1KMT2A | |
| SCHEMBL3495244 | 0.84 | SCD (0.38) | KDM4EALDH1A1POLBMEN1KMT2A | |
| SCHEMBL3498272 | 0.84 | NPC1 (0.40) | KDM4EALDH1A1MEN1KMT2ASMN1; SMN2 | |
| SCHEMBL5223852 | 0.84 | ALDH1A1 (0.41) | KDM4EALDH1A1KMT2ASMN1; SMN2CNR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1934220-A1 | INHIBITORS OF THE HIV INTEGRASE ENZYME | Pfizer Products Incorporated (US) | 2008-06-25 | — | — | EP | disclosed |
| US-20070099915-A1 | INHIBITORS OF THE HIV INTEGRASE ENZYME | PFIZER INC. | 2007-05-03 | — | — | US | disclosed |
| US-20070099915-A1 | INHIBITORS OF THE HIV INTEGRASE ENZYME | PFIZER INC. | 2007-05-03 | — | — | US | disclosed |
| US-20070099915-A1 | INHIBITORS OF THE HIV INTEGRASE ENZYME | PFIZER INC. | 2007-05-03 | — | — | US | disclosed |
| WO-2007042883-A1 | INHIBITORS OF THE HIV INTEGRASE ENZYME | PFIZER PRODUCTS INC. (US) | 2007-04-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070099915-A1 | INHIBITORS OF THE HIV INTEGRASE ENZYME | IMPDH1, INTS9, TYMP | KDM4E 821/4885ALDH1A1 437/4885POLB 34/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.